Propanc Biopharma, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2019, the first quarter of the company’s fiscal year ending June 30, 2020. The financial statements are unaudited. The filing describes Propanc as a development-stage biopharmaceutical company; its lead candidate, PRP, remained preclinical, and it had no marketed products.
Financial performance and liquidity
- Revenue: $0, unchanged from the comparable 2018 quarter.
- Operating expenses: $909,418, up from $448,871. Administration expense rose to $833,414 from $384,600; research and development expense was $65,372, versus $56,193.
- Net loss: $1,491,940, compared with $2,124,936. The 2019 result included a $518,956 gain from changes in derivative fair value and a $108,894 Australian R&D tax-credit benefit. Interest expense was $675,225; foreign-currency transaction loss was $535,150.
- Per-share loss: $1.41, compared with $10.00; weighted-average shares were 1,054,433 versus 224,965. Share and per-share amounts reflect the one-for-500 reverse split.
- Cash flow: Operating cash use was $726,331, up from $419,196. Financing provided $865,000 net, principally from convertible notes; cash increased by $93,729 to $96,123.
- Balance sheet at September 30: Current assets were $147,835 and current liabilities $4,717,234, a $4,569,399 working-capital deficit. Total assets were $197,663, total liabilities $4,739,395, and stockholders’ deficit $4,541,732.
- Debt: Convertible notes and related accrued interest, net of discounts and premiums, were reported at $2,547,085. The company also disclosed $254,308 of embedded conversion-option liabilities. Some notes were past maturity; the filing states the company was in default on certain notes for $305,749 of principal and accrued interest and was negotiating extensions.
Changes, outlook, and material risks
- Net loss narrowed year over year, but operating loss increased by about $460,500. The improvement in reported net loss was substantially affected by the derivative fair-value change and the tax credit; the prior-year quarter included a $1,185,871 gain on debt extinguishment.
- Administration costs increased due to, among other items, fundraising, investor-relations, legal, consulting, insurance, communications, and personnel expenses. Management attributed the higher R&D spending primarily to developing a method to measure PRP and its active constituents in human serum.
- Management said existing cash was insufficient for the next 12 months and that the company depended on additional debt or equity financing. The statements identify substantial doubt about the company’s ability to continue as a going concern. Financing may dilute shareholders or be unavailable on acceptable terms.
- Subject to raising sufficient capital, management outlined plans to prepare and submit a clinical trial application for PRP during 2020 and pursue a first-in-human Phase Ib study. These are conditional plans, not assured milestones; the filing also describes trial-site and logistics preparation extending into 2021.
- New convertible-note financing during the quarter included variable-price conversion terms, significant discounts or premiums, and warrants issued with the Auctus financing. These arrangements, along with conversions into shares, create potential dilution. The filing reports 20,500,465 shares reserved for lender requirements at quarter-end.
- Material contingencies include a former law firm’s lawsuit seeking $150,000 and a former consultant’s demand for approximately $400,000 plus 60,000 shares. The company disputes both claims; it says no loss contingency could be estimated for the consultant demand. Accrued IRS penalties and interest of at least $30,000 were also disclosed.
- Disclosure controls were deemed ineffective at September 30, 2019. The filing identifies material weaknesses involving undocumented controls, limited segregation of duties, no audit committee, and insufficient financial-reporting review and U.S. GAAP expertise.
Key facts investors should verify
- Whether financing was secured after quarter-end, including the availability and terms of the disclosed equity line, and whether proceeds support operations and planned clinical work.
- The status, maturity extensions, default terms, and potential share dilution associated with outstanding convertible notes and lender share reserves.
- Progress and updated timing for PRP development, clinical-trial application preparation, and any first-in-human study.
- Developments in the Foley Shechter lawsuit and Regal Consulting demand, including any change in the estimated exposure.
- Whether the company remedied its material weaknesses and whether disclosure controls became effective.
- The filing reports 1,169,981 common shares issued at September 30, but 1,311,531 shares issued and outstanding as of November 11; investors should reconcile the subsequent share activity.